22 results
253G3
STSS
Sharps Technology Inc
4 Jun 24
Offering circular supplement
5:03pm
Executive Officer and Chief Financial Officer, and retain the services of additional personnel, as needed, on an independent contractor basis to support R&D, Finance … , Research and Development (“R&D”) expenses decreased to $1,605,547 compared to $2,280,933 for the year ended December 31, 2022. The decrease
424B4
7ww6kvu4q7m6nn06hzag
25 Apr 23
Prospectus supplement with pricing info
4:15pm
10-K
nshzg 8m3uhxd1ckh
31 Mar 23
Annual report
4:17pm
8-K
EX-99.1
dultv 5lpi7e4tdvqap4
14 Jul 22
Sharps Technology Completes Acquisition of Safegard Medical Syringe Manufacturing Facility
4:05pm
8-K
EX-99.1
pyix70t4
8 Jun 22
Sharps Technology Announces Letter to Shareholders
4:10pm
10-Q
321d458msd2eixc4
25 May 22
Quarterly report
5:29pm
424B4
c1r5ma
15 Apr 22
Prospectus supplement with pricing info
4:48pm
S-1
xtnfdk08
18 Mar 22
IPO registration
5:23pm
DRSLTR
nkicqw0n7u0py
21 Jan 22
Correspondence regarding draft registration statement
12:00am